AstraZeneca PLC (NASDAQ:AZN) Shares Sold by AdvisorNet Financial Inc

AdvisorNet Financial Inc trimmed its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 4.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 21,314 shares of the company’s stock after selling 1,065 shares during the period. AdvisorNet Financial Inc’s holdings in AstraZeneca were worth $1,396,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of AZN. Meeder Advisory Services Inc. bought a new stake in AstraZeneca in the 2nd quarter valued at about $206,000. Brown Brothers Harriman & Co. increased its stake in shares of AstraZeneca by 3.7% in the second quarter. Brown Brothers Harriman & Co. now owns 6,062 shares of the company’s stock valued at $473,000 after purchasing an additional 216 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of AstraZeneca by 62.4% during the second quarter. Massachusetts Financial Services Co. MA now owns 27,329 shares of the company’s stock valued at $2,131,000 after buying an additional 10,500 shares during the last quarter. Sofinnova Investments Inc. boosted its position in shares of AstraZeneca by 34.3% during the second quarter. Sofinnova Investments Inc. now owns 801,417 shares of the company’s stock worth $62,503,000 after buying an additional 204,704 shares during the period. Finally, Wealth Alliance grew its holdings in AstraZeneca by 5.9% in the 2nd quarter. Wealth Alliance now owns 17,440 shares of the company’s stock worth $1,360,000 after buying an additional 975 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Trading Down 0.5 %

Shares of AstraZeneca stock opened at $65.37 on Wednesday. The business has a fifty day simple moving average of $65.98 and a 200-day simple moving average of $74.69. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The firm has a market cap of $202.69 billion, a price-to-earnings ratio of 31.28, a price-to-earnings-growth ratio of 1.19 and a beta of 0.46. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The company had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. AstraZeneca’s revenue was up 18.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.87 EPS. On average, equities analysts forecast that AstraZeneca PLC will post 4.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, AstraZeneca currently has a consensus rating of “Buy” and an average target price of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.